These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 23465686

  • 1. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
    Martínez-Martín P, Hernández B, Ricart J, FAST Study Group.
    Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686
    [Abstract] [Full Text] [Related]

  • 2. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
    Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A, FIRST-STEP Study Group.
    Mov Disord; 2009 Mar 15; 24(4):541-50. PubMed ID: 19058133
    [Abstract] [Full Text] [Related]

  • 3. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.
    Ann Neurol; 2010 Jul 15; 68(1):18-27. PubMed ID: 20582993
    [Abstract] [Full Text] [Related]

  • 4. Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.
    Trenkwalder C, Kuoppamäki M, Vahteristo M, Müller T, Ellmén J.
    Neurology; 2019 Mar 26; 92(13):e1487-e1496. PubMed ID: 30824559
    [Abstract] [Full Text] [Related]

  • 5. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
    Delea TE, Thomas SK, Hagiwara M, Mancione L.
    Curr Med Res Opin; 2010 Jul 26; 26(7):1543-52. PubMed ID: 20429819
    [Abstract] [Full Text] [Related]

  • 6. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS, Herawati L, Wan Y, Movement Disorder Society of Australia Clinical Research and Trials Group, QUEST-AP Study Group.
    Mov Disord; 2009 Jan 15; 24(1):25-31. PubMed ID: 18846551
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ, Lees A, Apajasalo M, Pitkänen A, Turunen H.
    Curr Med Res Opin; 2005 Jul 15; 21(7):1005-14. PubMed ID: 16004667
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M, Leinonen M, Poewe W.
    J Neural Transm (Vienna); 2015 Dec 15; 122(12):1709-14. PubMed ID: 26347184
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
    Groenendaal H, Tarrants ML, Armand C.
    Clin Drug Investig; 2010 Dec 15; 30(11):789-98. PubMed ID: 20818839
    [Abstract] [Full Text] [Related]

  • 11. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
    Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, Dillmann U, Rubens R, Kell S, Gupta S.
    Parkinsonism Relat Disord; 2014 Dec 15; 20(12):1335-40. PubMed ID: 25306200
    [Abstract] [Full Text] [Related]

  • 12. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
    Reichmann H, Emre M.
    Expert Rev Neurother; 2012 Feb 15; 12(2):119-31. PubMed ID: 22288667
    [Abstract] [Full Text] [Related]

  • 13. Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis.
    Liao X, Wu N, Liu D, Shuai B, Li S, Li K.
    Neurol Sci; 2020 Aug 15; 41(8):2045-2054. PubMed ID: 32162166
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J, US01 Study Team.
    Arch Neurol; 2004 Oct 15; 61(10):1563-8. PubMed ID: 15477510
    [Abstract] [Full Text] [Related]

  • 16. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
    Eggert K, Skogar O, Amar K, Luotonen L, Kuoppamäki M, Leinonen M, Nissinen H, Oertel W.
    J Neural Transm (Vienna); 2010 Mar 15; 117(3):333-42. PubMed ID: 20013007
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV, Odinak MM, Mogil'naia VI, Sologub OS, Sakharovskaia AA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009 Mar 15; 109(1):51-4. PubMed ID: 19156087
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.